D.J.L. MacGowan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
D.J.L. MacGowan has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
B. Polsky
From the ALS Center (D.J.L.M.), Department of Neurology (S.N.S., T.E.I.), Beth Israel Medical Center, Albert Einstein College of Medicine, New York; and Retrovirology Laboratory (K.-N.L., P.B., B.P.), St. Luke's Roosevelt Medical Center, New York, NY
1 shared publicationK.-N Liu
From the ALS Center (D.J.L.M.), Department of Neurology (S.N.S., T.E.I.), Beth Israel Medical Center, Albert Einstein College of Medicine, New York; and Retrovirology Laboratory (K.-N.L., P.B., B.P.), St. Luke's Roosevelt Medical Center, New York, NY
1 shared publicationM. Waldron
From the Departments of Neurology (Drs. MacGowan and Scelsa) and Infectious Diseases (Dr. Waldron), Beth Israel Medical Center, New York, NY
1 shared publicationP. Baron
From the ALS Center (D.J.L.M.), Department of Neurology (S.N.S., T.E.I.), Beth Israel Medical Center, Albert Einstein College of Medicine, New York; and Retrovirology Laboratory (K.-N.L., P.B., B.P.), St. Luke's Roosevelt Medical Center, New York, NY
1 shared publicationS. N. Scelsa
From the ALS Center (D.J.L.M.), Department of Neurology (S.N.S., T.E.I.), Beth Israel Medical Center, Albert Einstein College of Medicine, New York; and Retrovirology Laboratory (K.-N.L., P.B., B.P.), St. Luke's Roosevelt Medical Center, New York, NY
1 shared publicationS.N. Scelsa
From the Departments of Neurology (Drs. MacGowan and Scelsa) and Infectious Diseases (Dr. Waldron), Beth Israel Medical Center, New York, NY
1 shared publication
Latest Publications
- 29 May 2007
- Published by Wolters Kluwer Health in Neurology
- Vol. 68 (22) , 1944-1946
A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS
Reverse transcriptase has been detected in the serum of HIV-negative patients with amyotrophic lateral sclerosis (ALS). An ALS-like disorder in HIV-positive patients can remit with antiretroviral therapy. Using the product enhanced assay technique, we measured reverse transcriptase activity in the serum and CSF of 23 HIV-negative patients with ALS and 21 neurologic disease controls. Results for CSF were not significant, whereas reverse transcriptase was detected in 56% of ALS sera vs 19% of controls.
- 29 May 2007
- Published by Wolters Kluwer Health in Neurology
- Vol. 68 (22) , 1944-1946
A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS
Reverse transcriptase has been detected in the serum of HIV-negative patients with amyotrophic lateral sclerosis (ALS). An ALS-like disorder in HIV-positive patients can remit with antiretroviral therapy. Using the product enhanced assay technique, we measured reverse transcriptase activity in the serum and CSF of 23 HIV-negative patients with ALS and 21 neurologic disease controls. Results for CSF were not significant, whereas reverse transcriptase was detected in 56% of ALS sera vs 19% of controls.
- 25 September 2001
- Published by Wolters Kluwer Health in Neurology
- Vol. 57 (6) , 1094-1097
An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy
A 32-year-old woman presenting with a rapidly progressive ALS-like syndrome was found to be HIV positive with a CD4 count of 44/mm3. The patient recovered completely during 1 year after treatment with nelfinavir, zidovudine, and lamivudine, and recovery is sustained nearly 4 years later. Recovery was accompanied by HIV RNA becoming undetectable in plasma and CSF.
- 25 September 2001
- Published by Wolters Kluwer Health in Neurology
- Vol. 57 (6) , 1094-1097
An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy
A 32-year-old woman presenting with a rapidly progressive ALS-like syndrome was found to be HIV positive with a CD4 count of 44/mm3. The patient recovered completely during 1 year after treatment with nelfinavir, zidovudine, and lamivudine, and recovery is sustained nearly 4 years later. Recovery was accompanied by HIV RNA becoming undetectable in plasma and CSF.